share_log

Invivyd | 8-K: Current report

SEC announcement ·  May 22 19:09
Summary by Futu AI
On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of...Show More
On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of growth, particularly as Invivyd commercializes its first product and advances its proprietary tools for variant analysis and predictive modeling. The press release also highlighted the recent emergency use authorization (EUA) granted by the U.S. FDA for Invivyd's monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals, marking a significant milestone for the company.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.